Authors:
O'Grady KAF, Grimwood K, Cripps A, Mulholland EK, Morris P, Torzillo PJ, …
Richmond P, Thornton R, et al.
Authors notes:
Trials. 2013;14(1):282
Keywords:
Bronchiectasis, Child, Chronic suppurative lung disease, Non-typeable Haemophilus influenzae, Pneumococcal conjugate vaccines, Protracted bacterial bronchitis, Randomised controlled trial, Respiratory exacerbations, Streptococcus pneumoniae
Abstract:
Recurrent protracted bacterial bronchitis (PBB), chronic suppurative lung disease (CSLD) and bronchiectasis are characterised by a chronic wet cough and are important causes of childhood respiratory morbidity globally.
Haemophilus influenzae and Streptococcus pneumoniae are the most commonly associated pathogens.
As respiratory exacerbations impair quality of life and may be associated with disease progression, we will determine if the novel 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) reduces exacerbations in these children.
As H. influenzae is the most common bacterial pathogen associated with these chronic respiratory diseases in children, a novel pneumococcal conjugate vaccine that also impacts upon H. influenzae and helps prevent respiratory exacerbations would assist clinical management with potential short- and long-term health benefits.
Our study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.